- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348500
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection
Study Overview
Detailed Description
Patients admitted to the hospital with COVID-19 disease with signs of pulmonary involvement will be randomized to receive the anti-IL-6 drug clazakizumab 25mg IV or placebo. Patients will be followed for improvements in clinical symptoms and laboratory parameters which are part of our COVID-19 lab panel described below. Patients will receive standard of care (SOC) supportive treatment and will be followed for 14 days. If a patient from either group progresses to the need for mechanical ventilation and/or ECMO, or develops clinical signs of deteriorating COVID-19 disease, and there are no serious treatment related SAEs, at the discretion of the investigator or treating physician, the patient may receive a single dose of open-label clazakizumab 25mg IV. A minimum of 24 hours should elapse between the first dose of IP and this dose of open-label clazakizumab.
Enrolled patients will receive clazakizumab 25 mg or placebo (0.9% saline) given by IV infusion over 30 minutes. Clazakizumab will be administered in 50 mL of 0.9% saline on Day 1. COVID-19 lab panel and clinical parameters will be monitored to determine if patients are progressing towards need for ventilation and/or ECMO. The parameters below will be monitored and patient status will be assessed by the clinical team.
If patients do develop these criteria, open-label clazakizumab 25 mg IV may be administered as discussed above. A minimum of 24 hours should elapse between the first dose of IP and this dose of open-label clazakizumab. Patients ventilated with or without ECMO will continue to be monitored post-treatment for signs of improvement, (i.e., decreasing FiO2 requirements, chest X-ray (CXR) improvements, C-reactive protein (CRP) reductions, extubation and discharge home) or death.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >18 at the time of screening
- Subject must be able to understand and provide informed consent
- Hospitalized with COVID-19 (+) disease (confirmed by polymerase chain reaction (PCR) assay from any specimen (e.g. respiratory, blood, urine, stool, other bodily fluid))
- Not on mechanical ventilation and/or ECMO
Evidence of pulmonary involvement with at least 2 of the following:
- Oxygen saturation (SpO2) at rest in ambient air with SpO2 ≤ 94%
- Tachypnea with resting respiration rate > 25 breaths/minute
- Partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) ≤ 300 mmHg
- Chest imaging (radiograph, CT scan, or lung ultrasound) with abnormalities consistent COVID-19 pneumonia
- C-reactive protein (CRP) >35 mg/L
Exclusion Criteria:
- Previous hypersensitivity or allergic reactions to clazakizumab
- Lactating or pregnant females
- Subjects with latent Tuberculosis (TB) and who are not receiving treatment
- Subjects with active TB
- A significantly abnormal general serum screening lab result defined as a White Blood Count (WBC) < 3.0 X 103/ml, a Hgb < 8.0 g/dL, a platelet count < 50 X 103/ml, a serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) > 5x upper limit normal
- Participation in another clinical trial investigating COVID-19 aimed agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Clazakizumab
25 mg in 50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
|
IV Infusion
|
Placebo Comparator: Placebo
50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
|
IV Infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Clazakizumab for the Treatment of Patients With COVID-19 Disease
Time Frame: 14 days
|
Number of severe adverse events (SAEs) that are unusual, unexpected, or assessed as related to the investigational product (IP)
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Survival at 28 Days
Time Frame: 28 days
|
Number of patients alive at 28 days
|
28 days
|
Patient Survival at 60 Days
Time Frame: 60 days
|
Number of patients alive at 60 days
|
60 days
|
Number of Patients Requiring the Dose of Open-label Clazakizumab
Time Frame: 14 days
|
Number of patients requiring the dose of open-label clazakizumab
|
14 days
|
Number of Days in Intensive Care Unit (ICU)
Time Frame: 60 days
|
Number of days in ICU compared to placebo
|
60 days
|
Number of Days in Hospital
Time Frame: 60 days
|
Number of days in hospital compared to placebo
|
60 days
|
Number of Patients Requiring Mechanical Ventilation and/or Extracorporeal Membrane Oxygenation (ECMO)
Time Frame: 14 days
|
Number of patients requiring mechanical ventilation and/or ECMO at 14 days after the first administered dose in comparison to placebo
|
14 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00000644
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Clazakizumab
-
Medical University of ViennaCharite University, Berlin, Germany; University of Alberta; CSL BehringCompleted
-
NYU Langone HealthCompleted
-
Columbia UniversityNYU Langone Health; CSL BehringTerminated
-
Anne B. NewmanCSL BehringRecruitingImproving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study (RIGHT)Inflammation | FrailtyUnited States
-
The Methodist Hospital Research InstituteUnknown
-
Stanley Jordan, MDActive, not recruitingKidney Transplant Rejection | Kidney Transplant; Complications | Antibody-mediated Rejection | Transplant Glomerulopathy | Transplant Glomerulopathy - Late Form | Transplant Glomerulopathy - Early FormUnited States
-
CSL BehringCompletedRheumatoid ArthritisItaly, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
-
CSL BehringActive, not recruitingEnd Stage Kidney Disease | Atherosclerotic Cardiovascular DiseaseUnited States, Australia, Belgium, Canada, Germany
-
Stanley Jordan, MDActive, not recruitingKidney Failure, Chronic | End-Stage Renal Disease | Kidney Transplant; Complications | Antibody-mediated Rejection | Kidney Transplant Failure and Rejection | Transplant;Failure,Kidney | Transplant GlomerulopathyUnited States
-
CSL BehringTerminatedCrohn's DiseaseGermany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom